12286 J. Am. Chem. Soc., Vol. 120, No. 47, 1998
Nozary et al.
Preparation of 4-Dodecyloxyphenol (17). p-Hydroquinone (5.5
g, 50 mmol), 1-bromododecane (12.46 g, 50 mmol), and potassium
hydrogen carbonate (5.0 g, 50 mmol) were refluxed in dioxane/water
(1:1, 200 mL) for 12 h. Dioxane was distilled and the pH adjusted to
3.0 with concentrated hydrochloric acid (37%). The resulting aqueous
phase was extracted with dichloromethane (3 × 30 mL), and the
combined organic phases were dried (Na2SO4) and evaporated to
dryness. The crude product was purified by column chromatography
(silica gel; CH2Cl2) to give 4.2 g (14.6 mmol, yield 29%) of 13 as a
white powder. Mp 74-75 °C. 1H NMR in CDCl3: δ 0.88 (3H, t, J3
) 7 Hz), 1.25-1.75 (20H, m), 3.89 (2H, t, J3 ) 7 Hz), 4.42 (1H, s),
6.75 (2H, dd, J3 ) 9 Hz, J4 ) 2 Hz), 6.78 (2H, dd, J3 ) 9 Hz, J4 ) 2
Hz). EI-MS: m/z 278.3 (M+). The same procedure was used to prepare
18 from p-hydroquinone and 1-bromohexadecane (yield ) 20%). Mp
85 °C. 1H NMR in CDCl3: δ 0.88 (3H, t, J3 ) 7 Hz), 1.25-1.75
(29H, m), 3.89 (2H, t, J3 ) 7 Hz), 6.75 (2H, dd, J3 ) 9 Hz, J4 ) 2
Hz), 6.78 (2H, dd, J3 ) 9 Hz, J4 ) 2 Hz). EI-MS: m/z 334 (M+).
Preparation of 4-Dodecyloxybenzyl Alcohol (20). LiAlH4 (247
mg, 6.53 mmol) was dissolved in dry tetrahydrofuran (90 mL), and
4-dodecyloxybenzoic acid (19, 2.0 g, 6.53 mmol) dissolved in tetrahy-
drofuran (10 mL) was slowly added under an inert atmosphere. The
resulting mixture was refluxed for 10 h. The remaining LiAlH4 was
destroyed with an excess of water, and the resulting heterogeneous
mixture was evaporated to dryness and partitioned between CH2Cl2
and water. The organic phase was carefully separated and the aqueous
phase extracted with dichloromethane (3 × 30 mL), and the combined
organic phases were filtered, dried (Na2SO4), and evaporated to dryness.
The crude product was crystallized from CH2Cl2/hexane to give 1.6 g
(5.48 mmol, yield 84%) of 20 as a white powder. Mp 67 °C. 1H
NMR in CDCl3: δ 0.88 (3H, t, J3 ) 7 Hz), 1.3-1.8 (20H, m), 3.95
(2H, t, J3 ) 7 Hz), 4.62 (2H, s), 6.88 (2H, d, J3 ) 9 Hz), 7.28 (2H, dd,
J3 ) 9 Hz). EI-MS: m/z 292 (M+).
and 2,6-bis{1-ethyl-5-[4-(R-oxy)phenoxymethyl]benzimidazol-2-yl}-
pyridine (R ) methyl, L13, yield 84%; R ) dodecyl, L14, yield 82%;
and R ) hexadecyl, L15, yield 79%) with respectively 14, 16-18 as
sidearms.
L12. Mp 89 °C. 1H NMR in CDCl3: δ 0.87 (12H, t, J3 ) 7 Hz),
1.42 (6H, t, J3 ) 7 Hz), 1.2-1.8 (80H, m), 4.03 (4H, t, J3 ) 7 Hz),
4.04 (4H, t, J3 ) 7 Hz), 4.80 (4H, q, J3 ) 7 Hz), 5.51 (4H, s), 6.85
(2H, d, J3 ) 9 Hz), 7.49 (4H, m), 7.58 (2H, d, J4 ) 2 Hz), 7.70 (2H,
dd, J3 ) 9 Hz, J4 ) 2 Hz), 8.00 (2H, s), 8.10 (1H, t, J3 ) 8 Hz), 8.35
(2H, d, J3 ) 8 Hz). 13C NMR in CDCl3: δ 14.15, 15.47 (primary C);
22.73, 26.01, 29.10, 29.24, 29.41, 29.43, 29.66, 29.80, 31.96, 40.07,
66.86, 69.05, 69.38 (secondary C); 110.45, 111.93, 114.48, 120.12,
122.43, 123.78, 124.48, 126.18, 138.42 (tertiary C); 131.62, 135.65,
148.58, 149.59, 150.12, 153.37, 166.46, 180.97 (quaternary C). ES-
MS (CH2Cl2): m/z 1372.9 ([M + H]+).
L13. Mp 195 °C. 1H NMR in CDCl3: δ 1.37 (6H, t, J3 ) 7 Hz),
3.77 (6H, s), 4.80 (4H, q, J3 ) 7 Hz), 5.19 (4H, s), 6.84 (4H, d, J3 )
9 Hz), 6.96 (4H, d, J3 ) 8 Hz), 7.46 (2H, d, J3 ) 8 Hz), 7.50 (2H, d,
J3 ) 8 Hz), 7.92 (2H, s), 8.06 (1H, t, J3 ) 8 Hz), 8.35 (2H, d, J3 ) 8
Hz). 13C NMR in CDCl3: δ 15.49, 55.77 (primary C); 22.75, 39.97,
71.15 (secondary C); 110.46, 114.69, 115.99, 119.69, 123.58, 125.79,
135.77 (tertiary C); 132.13, 138.18, 142.90, 149.90, 150.37, 153.00,
153.90 (quaternary C). ES-MS (CH2Cl2): m/z 640.1 ([M + H]+).
L14. Mp 188 °C. 1H NMR in CDCl3: δ 0.88 (6H, t, J3 ) 7 Hz),
1.42 (6H, t, J3 ) 7 Hz), 1.2-1.8 (40H, m), 3.90 (4H, t, J3 ) 7 Hz),
4.80 (4H, q, J3 ) 7 Hz), 5.18 (4H, s), 6.84 (4H, d, J3 ) 9 Hz), 6.95
(4H, d, J3 ) 8 Hz), 7.46 (2H, d, J3 ) 8 Hz), 7.50 (2H, d, J3 ) 8 Hz),
7.97 (2H, s), 8.06 (1H, t, J3 ) 8 Hz), 8.35 (2H, d, J3 ) 8 Hz). 13C
NMR in CDCl3: δ 14.17, 15.49 (primary C); 22.73, 26.10, 29.45, 29.65,
31.96, 39.97, 66.68, 71.13 (secondary C); 110.44, 115.44,115.94,
119.68, 123.60, 125.80, 138.18 (tertiary C); 132.20, 135.75, 142.05,
149.93, 150.33, 152.88, 153.53 (quaternary C). ES-MS (CH2Cl2): m/z
948.5 ([M + H]+).
Preparation of 4-Dodecyloxybenzyl Bromide (21). 4-Dodecyl-
oxybenzyl alcohol (20, 1.2 g, 4.2 mmol) and phosphorus tribromide
(550 mg, 2.04 mmol) were refluxed for 15 h in dichloromethane (75
mL). Excess PBr3 was hydrolyzed with water (20 mL) and brine (80
mL). The organic phase was separated and the aqueous phase extracted
with dichloromethane (3 × 30 mL), and the combined organic phases
were dried (Na2SO4) and evaporated to dryness. The crude product
was crystallized from CH2Cl2 to give 1.46 g (4.10 mmol, yield 99%)
of 21 as white microcrystals. Mp 42-43 °C. 1H NMR in CDCl3: δ
0.88 (3H, t, J3 ) 7 Hz), 1.3-1.8 (20H, m), 3.95 (2H, t, J3 ) 7 Hz),
4.51 (2H, s), 6.85 (2H, d, J3 ) 9 Hz), 7.30 (2H, dd, J3 ) 9 Hz). EI-
MS: m/z 354/356 (M+).
L15. Mp 184 °C. 1H NMR in CDCl3: δ 0.88 (6H, t, J3 ) 7 Hz),
1.42 (6H, t, J3 ) 7 Hz), 1.2-1.8 (56H, m), 3.90 (4H, t, J3 ) 7 Hz),
4.80 (4H, q, J3 ) 7 Hz), 5.18 (4H, s), 6.84 (4H, d, J3 ) 9 Hz), 6.95
(4H, d, J3 ) 8 Hz), 7.46 (2H, d, J3 ) 8 Hz), 7.50 (2H, d, J3 ) 8 Hz),
7.97 (2H, s), 8.06 (1H, t, J3 ) 8 Hz), 8.35 (2H, d, J3 ) 8 Hz). 13C
NMR in CDCl3: δ 14.17, 15.49 (primary C); 22.73, 26.10, 29.45, 29.65,
31.96, 39.97, 66.68, 71.13 (secondary C); 110.44, 115.44, 115.94,
199.68, 123.60, 125.80, 138.18 (tertiary C); 132.20, 135.75, 142.95,
149.93, 150.33, 152.88, 153.53 (quaternary C). ES-MS (CH2Cl2): m/z
1060.5 ([M + H]+).
Preparation of 2,6-Bis[1-ethyl-5-(4-dodecyloxy)benzyloxybenz-
imidazol-2-yl]pyridine (L16). A suspension of 2,6-bis(1-ethyl-5-
hydroxy-benzimidazol-2-yl)pyridine (11, 300 mg, 0.751 mmol) in
dichloromethane (10 mL) was reacted with tetra-n-butylammonium
hydroxide (0.38 M in methanol, 4.34 mL, 1.65 mmol). After complete
solubilization, the solvent was evaporated and the resulting salt dried
under vacuum and redissolved in dry dichloromethane (20 mL).
4-Dodecyloxybenzyl bromide (21, 586 mg, 1.65 mmol) in dry dichlo-
romethane (10 mL) was added and the solution refluxed for 10 h under
an inert atmosphere. The standard workup described for L11 gave 410
mg (0.43 mmol, yield 57%) of L16, which was crystallized from CH2-
Cl2/hexane. Mp 193 °C. 1H NMR in CDCl3: δ 0.88 (6H, t, J3 ) 7
Hz), 1.40 (6H, t, J3 ) 7 Hz), 1.3-1.8 (40H, m), 3.96 (4H, t, J3 ) 7
Hz), 4.77 (4H, q, J3 ) 7 Hz), 5.08 (4H, s), 6.91 (4H, d, J3 ) 9 Hz),
7.10 (2H, dd, J3 ) 8 Hz, J4 ) 2 Hz), 7.36 (2H, d, J3 ) 8 Hz), 7.40
(4H, d, J3 ) 8 Hz), 7.42 (2H, s), 8.04 (1H, t, J3 ) 8 Hz), 8.32 (2H, d,
J3 ) 8 Hz). 13C NMR in CDCl3: δ 14.17, 15.56 (primary C); 22.74,
26.00, 29.41, 31.96, 39.92, 68.10, 70.59 (secondary C); 103.61, 110.72,
114.63, 114.95, 125.47, 129.34, 138.00 (tertiary C); 128.90, 155.81,
159.07 (quaternary C). ES-MS (CH2Cl2): m/z 948.3 ([M + H]+). The
same procedure was used for the syntheses of 2,6-bis[1-ethyl-5-(4-
dodecyloxybenzoic ester) benzimidazol-2-yl]pyridine (L17) from the acyl
chloride of 19 (yield 60%).
Preparation of 2,6-Bis[1-ethyl-5-(4-dodecyloxybenzoic acid) meth-
yl ester benzimidazol-2-yl]pyridine (L11). 4-Dodecyloxybenzoic acid
(19, 336 mg, 1.09 mmol) and tetra-n-butylammonium hydroxide (0.1
M in 2-propanol/methanol, 10.9 mL, 1.09 mmol) were dissolved in
dichloromethane (10 mL). The solvent was evaporated to dryness and
the resulting salt dried under vacuum. 2,6-Bis(1-ethyl-5-bromometh-
ylbenzimidazol-2-yl)pyridine (10, 200 mg, 0.361 mmol) in dry dichlo-
romethane (20 mL) was poured onto the salt under an inert atmosphere
and stirred for 48 h. Half-saturated aqueous NH4Cl (50 mL) was added,
the organic layer separated, and the aqueous phase extracted with CH2-
Cl2 (3 × 30 mL). The combined organic phases were dried (Na2SO4)
and evaporated to dryness, and the crude residue was purified by column
chromatography (silica gel; CH2Cl2/MeOH 100:0f99:1) to give 370
mg (0.369 mmol, yield 84%) of L11 as a white precipitate. Mp 103-
104 °C. 1H NMR in CDCl3: δ 0.88 (6H, t, J3 ) 7 Hz), 1.37 (6H, t,
J3 ) 7 Hz), 1.1-1.8 (40H, m), 4.00 (4H, t, J3 ) 7 Hz), 4.80 (4H, q,
J3 ) 7 Hz), 5.50 (4H, s), 6.90 (4H, d, J3 ) 9 Hz), 7.46 (2H, d, J3 )
8 Hz), 7.50 (2H, d, J3 ) 8 Hz), 7.97 (2H, s), 8.02 (4H, d, J3 ) 9 Hz),
8.07 (1H, t, J3 ) 8 Hz), 8.36 (2H, d, J3 ) 8 Hz). 13C NMR in CDCl3:
δ 14.18, 15.51 (primary C); 22.74, 26.03, 29.16, 29.41, 29.63, 29.69,
31.96, 39.99, 66.87, 68.26 (secondary C); 110.37, 114.09, 120.25,
122.38, 124.15, 125.82, 131.77, 138.00 (tertiary C); 131.21, 143.01,
145.69, 149.92, 150.48, 163.07, 166.40, 180.97 (quaternary C). ES-
MS (CH2Cl2): m/z 1004.6 ([M + H]+).
L17. Mp 226 °C. 1H NMR in CDCl3: δ 0.88 (6H, t, J3 ) 7 Hz),
1.40 (6H, t, J3 ) 7 Hz), 1.3-1.8 (40H, m), 4.60 (4H, t, J3 ) 7 Hz),
4.81 (4H, q, J3 ) 7 Hz), 7.00 (4H, d, J3 ) 9 Hz), 7.23 (2H, dd, J3 )
8 Hz, J4 ) 2 Hz), 7.51 (2H, d, J3 ) 8 Hz), 7.68 (4H, d, J4 ) 2 Hz),
8.08 (1H, t, J3 ) 8 Hz), 8.10 (4H, d, J3 ) 9 Hz), 8.36 (2H, d, J3 ) 8
Preparation of Ligands L12-L15. The same procedure as above
was used for the syntheses of 2,6-bis{1-ethyl-5-[3,4-bis(dodecyloxy)-
benzoic acid] methyl ester benzimidazol-2-yl}pyridine (L12, yield 80%)